Rachel V. Rose, JD, MBA is a Principal with Rachel V. Rose – Attorney at Law, P.L.L.C. (Houston, TX).
Ms. Rose advises clients on compliance, transactions, government enforcement actions and litigation in healthcare, cybersecurity, corporate and securities law, while successfully representing plaintiffs in False Claims Act and Dodd-Frank whistleblower cases.
A Fellow of the Federal Bar Association and the American Bar Association. Currently, she serves on the Foundation Federal Bar Association Board of Directors, is a Member and Immediate Past-Chair of the Federal Bar Association’s Government Relations Committee, and an advisory board member of the Federal Bar Association’s Qui Tam Section. Ms. Rose is the co-editor of the American Health Law Association’s Enterprise Risk Management Handbook for Healthcare Entities (2nd Edition), as well as a co-author of the ABA’s books The ABCs of ACOs, What Are International HIPAA Considerations? and International HIPAA, Privacy, and Security Law Considerations. She has also co-authored a variety of chapters for medical textbooks.
In addition to being extensively published and a sought-after presenter and quoted expert, Ms. Rose holds an MBA with minors in healthcare and entrepreneurship from Vanderbilt University, and a law degree from Stetson University College of Law, where she graduated with various honors. She also holds an Executive Certificate in Negotiation from Harvard Law School.
She has been named consecutively to SuperLawyers (healthcare), the Texas Bar College, the National Women Trial Lawyers Association’s Top 25, Houstonia Magazine’s Top Lawyers (healthcare), the National Trial Lawyers Association’s Top 100, The Nation’s Top One Percent, as well as 1st Healthcare Compliance’s 2019 Top Presenter. Ms. Rose is also an Affiliated Member with the Baylor College of Medicine’s Center for Medical Ethics and Health Policy, where she teaches bioethics.
Federal Court Admissions: Supreme Court of the United States, Fifth Circuit, D.C. Circuit, CO, DC, SDTX, NDTX, EDTX and WDTX.
See www.rvrose.com for additional information.
In 2016, the term “materiality” as it relates to the False Claims Act made a splash in the 2016 U.S. Supreme Court’s Escobar Decision. Subsequently, motions arose contesting materiality in order to dismiss False Claims Act cases. A ...
Established in 1992, the 340B Drug Pricing Program has many nuances and applications to different situations. Fundamentally, it requires pharmaceutical manufacturers to sell outpatient drugs at significantly reduced prices to eligible safety-net hosp...
Recent court opinions, a lawsuit against OpenAI Foundation and OpenAI Group PBC aka ChatGPT for the unauthorized practice of law, and similar lawsuits for the unauthorized practice of medicine should be raising red flags for lawyers and doctors alike...
The False Claims Act continues to be the federal Government’s number one fraud fighting tool. Whistleblowers play a critical role in bringing fraud to the Government’s attention and lead to billions of dollars being returned to the federa...